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Previewsneurons from downstream regions? To
address these questions, one certainly
needs to first answer how adult-born
neurons mechanistically contribute to
brain functions, which remains the holy
grail of the field and may require direct
examination of newborn granule cells
during behavior in vivo. Second, what is
the mechanism underlying connectivity
changes in response to experience?
Does it depend on the activity of newborn
neurons or presynaptic partners? Or is it
simply a secondary effect of the altered
systemic environment, for example,
more secreted neurotrophic factors?
Third, is the postsynaptic innervation of
adult-born neurons to hilar neurons, CA3
neurons, and maybe others also experi-
ence dependent? The answer to these
questions may facilitate a complete un-
derstanding of adult neurogenesis func-
tion. Forth, how do other experiences
impact the integration process? For
instance, does stress, which negatively
regulates the generation and survival of
newborn neurons (Christian et al., 2014),
affect the number of presynaptic part-
ners? It is of note that laboratory mice
are typically housed in a non-enrichedenvironment as compared to their natural
habitats. Therefore, the observed pattern
in EE mice may mimic the natural pattern
in wild animals, while the laboratory
environment renders it less complex.
Other pathological conditions, such as
epileptic seizure and disease-causing
gene mutations (e.g., mutations in Fmrp
or Disc1), all lead to aberrant develop-
ment of adult-born neurons (Christian
et al., 2014). Understanding how potential
deficits in the connectivity of adult-
born neurons under these conditions
contribute to the brain dysfunctions will
certainly be of broad interest to the soci-
ety in general.REFERENCES
Bergami, M., Masserdotti, G., Temprana, S.G.,
Motori, E., Eriksson, T.M., Go¨bel, J., Yang,
S.M., Conzelmann, K.-K., Schinder, A.F., Go¨tz,
M., et al. (2015). Neuron 85, this issue,
710–717.
Christian, K.M., Song, H., and Ming, G.L. (2014).
Annu. Rev. Neurosci. 37, 243–262.
Deshpande, A., Bergami, M., Ghanem, A., Conzel-
mann, K.K., Lepier, A., Go¨tz, M., and Berninger, B.
(2013). Proc. Natl. Acad. Sci. USA 110, E1152–
E1161.Neuron 85,Ge, S., Sailor, K.A., Ming, G.L., and Song, H.
(2008). J. Physiol. 586, 3759–3765.
Ge, S., Yang, C.H., Hsu, K.S., Ming, G.L., and
Song, H. (2007). Neuron 54, 559–566.
Kempermann, G., Kuhn, H.G., and Gage, F.H.
(1997). Nature 386, 493–495.
Li, Y., Aimone, J.B., Xu, X., Callaway, E.M., and
Gage, F.H. (2012). Proc. Natl. Acad. Sci. USA
109, 4290–4295.
Ming, G.L., and Song, H. (2011). Neuron 70,
687–702.
Nissant, A., Bardy, C., Katagiri, H., Murray, K., and
Lledo, P.M. (2009). Nat. Neurosci. 12, 728–730.
Schmidt-Hieber, C., Jonas, P., and Bischofberger,
J. (2004). Nature 429, 184–187.
Song, J., Sun, J., Moss, J., Wen, Z., Sun, G.J., Hsu,
D., Zhong, C., Davoudi, H., Christian, K.M., Toni,
N., et al. (2013). Nat. Neurosci. 16, 1728–1730.
Tashiro, A., Sandler, V.M., Toni, N., Zhao, C., and
Gage, F.H. (2006). Nature 442, 929–933.
van Praag, H., Kempermann, G., and Gage, F.H.
(1999). Nat. Neurosci. 2, 266–270.
Vivar, C., Potter, M.C., Choi, J., Lee, J.Y., Stringer,
T.P., Callaway, E.M., Gage, F.H., Suh, H., and van
Praag, H. (2012). Nature communications 3, 1107.
Wickersham, I.R., Lyon, D.C., Barnard, R.J., Mori,
T., Finke, S., Conzelmann, K.K., Young, J.A., and
Callaway, E.M. (2007). Neuron 53, 639–647.Loosening Pain’s Grip
by Tightening TRPV1-TRPA1 InteractionsAndy D. Weyer1 and Cheryl L. Stucky1,*
1Department of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, 8701 Watertown Plank Road Milwaukee,
WI 53226, USA
*Correspondence: cstucky@mcw.edu
http://dx.doi.org/10.1016/j.neuron.2015.02.004
TRPA1 and TRPV1 are ion channels crucial for pain sensation. In this issue of Neuron, Weng et al. (2015)
demonstrate that the activity of TRPA1-TRPV1 heteromers is governed by Tmem100 and that disabling
Tmem100 may be a novel pharmacologic strategy to combat pain.Perhaps the area of greatest study within
the somatosensory field today is dedi-
cated toward ameliorating the devas-
tating effects of chronic pain, which
affects millions of Americans each year
and contributes substantially to health-
care expenditures (Institute of MedicineReport from the Committee on
Advancing Pain Research, Care, and Ed-
ucation, 2011). Opioids continue to be
the standard of care for pain reduction
in the acute setting but are unsuitable
for long-term use due to issues of depen-
dence and opioid-induced hypersensitiv-ity in some patients, whereas newer
drugs such as gabapentin are only effec-
tive in a subset of patient populations
(Moore et al., 2011). Therefore, the dis-
covery of new drugs is of paramount
importance clinically, and much research
is focused on the discovery of novelFebruary 18, 2015 ª2015 Elsevier Inc. 661
Figure 1. A Tmem100 Mutant May Help Relieve Mechanical
Hypersensitivity after Injury by Facilitating TRPV1 Inhibition of
TRPA1
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Previewsdrug targets and how they
contribute to pain behaviors.
Many molecules have been
implicated in contributing to
pain sensations, but no family
of transduction proteins has
been studied as extensively
as the Transient Receptor Po-
tential (TRP) ion channels (Ju-
lius, 2013). These channels
are activated in response to
a variety of chemical, thermal,
and mechanical stimuli. Spe-
cifically, the TRP Vanilloid 1
(TRPV1) and TRP Ankyrin 1
(TRPA1) channels have been
intensely studied based on
the crucial roles they seem
to play in the pain response.
Indeed, genetic knockouts of
these genes in mice lead to
significant reductions in pain
behaviors, buoying the argu-
ment that they are critical
for pain sensation (Caterina
et al., 2000; Kwan et al.,
2006).
Based on these strong data
in rodent models, pharma-
ceutical companies quickly
raced to develop antagonistsof TRPA1 and TRPV1 that could be used
clinically to limit the pain suffered by
millions of people around the world.
Unfortunately, like many drugs that pass
preclinical trials, antagonists of TRPV1
have so far proven to be unsatisfactory
for patient populations due to side effects
such as hyperthermia and prevention of
protective noxious heat sensation, and
TRPA1 antagonists, while showing some
signs of promise in clinical trials, have
yet to move past phase II clinical trials
(Kaneko and Szallasi, 2014). Some phar-
maceutical companies have even shelved
research and development on TRPA1 and
TRPV1 as pain targets due to these bar-
riers. Thus, new modes of reducing the
activity of TRP channels like TRPV1 and
TRPA1 must be considered if they are to
be used as suitable pharmacological
pain targets.
Since the interaction between TRPA1
and TRPV1 has been shown to be impor-
tant for their functional activity (Akopian,
2011), one potential way to target these
proteins is to disrupt their interactions
with each other. Although some research662 Neuron 85, February 18, 2015 ª2015 Elshas examined whether TRPA1 and
TRPV1 interact via signaling pathways
(Akopian, 2011), other studies have
shown that TRPA1 and TRPV1 physically
interact via the formation of heteromers
and that these heteromers confer distinct
properties to native sensory neurons
(Fischer et al., 2014; Salas et al., 2009;
Staruschenko et al., 2010). Therefore, tar-
geting the formation of TRPA1/V1 hetero-
mers or the interactions of these two ion
channels when in complex presents a
novel method for preventing TRP-medi-
ated pain.
In this issue of Neuron, Weng et al.
(2015) describe exciting research indi-
cating that a little-studied protein,
Tmem100, acts as a transmembrane
adaptor protein to govern the functional
and physical interaction between TRPA1
and TRPV1 in murine sensory neurons.
Tmem100 is a two-transmembrane pro-
tein located in a wide variety of tissues,
but importantly localizes its N and
C termini to the intracellular side of the
plasma membrane, allowing for interac-
tions with other proteins. Based on exper-evier Inc.imental data using transgenic,
molecular, and electrophys-
iological approaches, Weng
et al. (2015) parse apart
the effects of Tmem100 on
TRPA1 and TRPV1 and have
also helped reconcile incon-
gruities in the literature be-
tween genetic knockouts of
TRPA1 or TRPV1 and heterol-
ogous expression systems
(Salas et al., 2009).
Specifically, Weng et al.
(2015) show that in the
absence of Tmem100, TRPV1
forms a tight association with
TRPA1 that greatly inhibits
the activity of TRPA1 in
response to chemical agonists
but has no effect on TRPV1
agonism. In the presence
of Tmem100, however, the
physical association between
TRPA1 and TRPV1 is loos-
ened, leading to reduced
inhibition of TRPA1, thereby
allowing TRPA1 to have
increased open probabilities
in response to chemical
agonists. Through the use
of targeted mutations, Wenget al. (2015) then demonstrate that the
regulation of this interaction depends criti-
cally on a KRR motif in the C terminus of
Tmem100 and that mutation of just this
three amino acid sequence to a series of
three glutamines actually results in a stron-
ger inhibition of TRPA1 by TRPV1. Thus,
modifications to a small part of theC termi-
nus of Tmem100 provide a novel mode of
TRPA1 inhibition.
Critically, these results also carry over
to the behavioral level, as Tmem100/
animals show reductions in mechanical
pain behavior following inflammatory
injury. Additionally, injection of a cell
permeable peptide (CPP) consisting of
the mutated C terminus of Tmem100 is
able to partially ameliorate pain behav-
iors, opening the door for the use of this
molecule as a novel therapeutic (Figure 1).
Given that the CPP was injected subcuta-
neously, these results also suggest that
the Tmem100 CPP could serve as a rela-
tively non-invasive mode of pain inhibition
with fewer side effects due to local injec-
tion at the stimulus transduction site.
Importantly, basal mechanosensitivity
Neuron
Previewsand thermal sensitivity (both heat and
cold) are not affected by genetic deletion
of Tmem100 or injection of the cell perme-
able peptide. Since off-target thermoreg-
ulatory effects and blunting of normal
noxious sensation were two of the primary
reasons that inhibitors of TRPA1 and
TRPV1 did not pass clinical trials (Kaneko
andSzallasi, 2014), these data collectively
support Tmem100 as a strong viable
target for the alleviation of mechanical
pain.
It is pertinent to emphasize that these
experiments do not suggest that
Tmem100 is a panacea for chronic pain
conditions. On the behavioral level,
pharmacologic or genetic targeting of
Tmem100 is able to partially abrogate
the reduction in paw withdrawal thresh-
olds following short-term peripheral
inflammation but is unable to completely
normalize mechanical responses back to
baseline. This suggests that, as would
be expected, TRPA1 is not the only player
mediating mechanical pain sensation
following inflammatory injury. Addition-
ally, the experiments presented in this
issue of Neuron have only explored pain
responses on an acute timescale
following injury, and future studies must
determine whether targeting Tmem100
represents an effective strategy for treat-
ing pain conditions on a chronic scale,
which is a comparatively greater clinical
problem than acute pain (Committee on
Advancing Pain Research, Care, and Edu-
cation, 2011). Finally, the effects of
Tmem100 in other types of pain condi-
tions (i.e., neuropathic pain) and in dorsal
root ganglia from human tissue donors
will need to be assessed for a full appreci-
ation of the role of Tmem100 in pain
sensation in patients.
Given the strong data in this manuscript
indicating a role for Tmem100 in regu-
lating the interaction between TRPV1
and TRPA1, another interesting question
is what this molecule is doing in other tis-
sues and also in the 40% of neurons that
do not express either TRPA1 or TRPV1.
One possibility is that Tmem100 interacts
with other TRP channels in these neurons/tissues, or, based on its ability to strongly
regulate mechanical sensation, interacts
with novel mechanotransducers.
This study did not look at mechano-
transduction on the cellular level using
patch-clamp recordings, and it will be
quite compelling to examine how me-
chanically gated currents are affected by
the interaction of TRPA1 and Tmem100.
TRPA1 is thought to play a critical role in
amplifying mechanical responses and
may mediate slowly inactivating currents
on the cellular level in native sensory neu-
rons (Vilceanu and Stucky, 2010) but on
its own is not thought to be directly me-
chanically gated. It has recently been
demonstrated that the mechanically
gated ion channel Piezo2 is not respon-
sible for the mechanosensitivity of noci-
ceptive afferents (Ranade et al., 2014), in
which TRPA1, TRPV1, and Tmem100
appear to be expressed. Therefore,
further investigation of Tmem100’s ef-
fects on mechanical currents and identifi-
cation of additional binding partners may
shed light on how TRPA1 contributes to
mechanosensation and what proteins
are ultimately responsible for the detec-
tion of mechanical stimuli by nociceptive
afferents.
Also of note is that Tmem100 is ex-
pressed almost exclusively in peptidergic
neurons. A recent study examining
labeled lines for sensory coding in the pe-
riphery found that peptidergic neurons are
disposable for mechanosensation, both
under naive conditions and following in-
flammatory or neuropathic injury (McCoy
et al., 2013). Since peptidergic neurons
play a significant role in mediating neuro-
genic inflammation following peripheral
injury, it is possible that Tmem100
works in concert with TRPA1 and TRPV1
to mediate release of peptides such
as Calcitonin Gene-Related Peptide
(CGRP). CGRP could then act to either
sensitize non-peptidergic afferents to
mechanical stimuli directly or promote
release of sensitizing agents from immune
cells or keratinocytes to sensitize termi-
nals indirectly. This would perhaps ex-
plain why genetic deletion of Tmem100Neuron 85,had no effect on basal mechanosensitiv-
ity, and future studies will be needed to
resolve these discordant findings.
Ultimately, the findings presented here
by Weng et al. (2015) provide new life for
examining TRP channels as suitable phar-
macological pain targets, and may be the
impetus for new strategies to combat
pathological pain sensation.
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